This trial tests a new drug to treat painful skin condition hidradenitis suppurativa over a 54-week period.
- Hidradenitis Suppurativa
1 Primary · 18 Secondary · Reporting Duration: From Week 12 through Week 54
3 Treatment Groups
Povorcitinib Dose B
1 of 3
Povorcitinib Dose A
1 of 3
1 of 3
600 Total Participants · 3 Treatment Groups
Primary Treatment: Povorcitinib Dose B · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this research currently in the process of enrolling participants?
"The clinical trial is actively recruiting patients, as evidenced by the information posted on clinicaltrials.gov. This research endeavor was originally advertised on February 22nd 2023 and updated to its current version March 1st 2023." - Anonymous Online Contributor
Is Povorcitinib Dose B associated with any potential risks for patients?
"Our team has rated the safety of Povorcitinib Dose B as a 3 due to prior research demonstrating efficacy and numerous rounds of data confirming its security." - Anonymous Online Contributor
What is the scope of participants in this medical research?
"This trial necessitates the enrollment of 600 individuals that meet its specified inclusion criteria. Applicants have a choice between Investigative Site US226 in San Diego, Florida and Investigative Site US222 in San Francisco, Illinois." - Anonymous Online Contributor
Are there multiple Canadian sites that are facilitating this clinical investigation?
"Apart from the previously mentioned Investigative Sites in San Diego, Florida and Brandon, Indiana; this trial is also recruiting patients at US222 located in San Francisco as well twenty-nine other research centres." - Anonymous Online Contributor